Indacaterol Maleate
-
API Product :
Indacaterol Maleate
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Chronic Obstructive Pulmonary Disease(COPD)
-
Originator :
Novartis
-
CAS No. :
312753-06-3
-
Trade Name. :
Onbrez, Arcapta
-
Molecular Weight :
392.490 g/mol
-
Molecular Formula :
C24H28N2O3
Application
Indacaterol is used to treat trouble breathing and wheezing due to a certain ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and/or emphysema). It is used if your breathing problems are not controlled with other medication (such as a quick-relief inhaler).
General Description
Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009,[2] and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011.[3] It needs to be taken only once a day,[4] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.